Medulloblastoma – V9: 2023+
| Primary Site | Histology | Behavior | Year of Diagnosis |
|---|---|---|---|
| C700-C729 | 9362, 9470-9472, 9474-9478, 9501-9504, 9508 | 3 | 2023-9998, 9999, <BLANK> |
| C700-C722, C724-C729 | 9473 | 3 | 2023-9998, 9999, <BLANK> |
| C753 | 9362 | 3 | 2023-9998, 9999, <BLANK> |
Notes
**See table above for primary sites and histologies for this schema** C700: Cerebral meninges C701: Spinal meninges C709: Meninges, NOS C710: Cerebrum C711: Frontal lobe C712: Temporal lobe C713: Parietal lobe C714: Occipital lobe C715: Ventricle, NOS C716: Cerebellum, NOS C717: Brain stem C718: Overlapping lesion of brain C719: Brain, NOS C720: Spinal cord C721: Cauda equina C722: Olfactory nerve C723: Optic nerve C724: Acoustic nerve C725: Cranial nerve, NOS C728: Overlapping lesion of brain and central nervous system C729: Nervous system, NOS C753: Pineal Gland (9362 only) **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Brain and Spinal Cord, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **New schema for 2023+** * This is a new schema for cases diagnosed 2023+. * For cases diagnosed prior to 2023, see the following schemas * Brain (C700, C710-C719) * CNS Other (C701, C709, C720-C721, C728-C729) * Intracranial Gland (C753)Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | Yes |
NAACCR #390
dateOfDiagnosis |
None | ||
| Primary Site | Yes |
NAACCR #400
primarySite |
None | ||
| Histology | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | ||
| Behavior | Yes |
NAACCR #523
behaviorCodeIcdO3 |
None | ||
| Type of Reporting Source | No |
NAACCR #500
typeOfReportingSource |
None | ||
| Tumor Size Clinical | No |
NAACCR #752
tumorSizeClinical |
None | ||
| Tumor Size Pathological | No |
NAACCR #754
tumorSizePathologic |
None | ||
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 888 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 00 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | No |
NAACCR #764
summaryStage2018 |
None | ||
| Grade Clinical | 9 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 9 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI | |
| Grade Post Therapy Path (yp) | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI | |
| Brain Molecular Markers | 88 | No |
NAACCR #3816
brainMolecularMarkers |
NPCR SEER |
SSDI |
| Neoadjuvant Therapy | 9 | No |
NAACCR #1632
neoadjuvantTherapy |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Clinical Response | 99 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
SEER 2021– | SSDI 2021– |
| Neoadjuvant Therapy – Treatment Effect | 9 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
SEER 2021– | SSDI 2021– |
Initial Context
Outputs
| Name | Default Value | Description | NAACCR Item | Metadata |
|---|---|---|---|---|
| Schema ID | 09724 |
NAACCR #3800
schemaId |
None | |
| Derived Version | {{ctx_alg_version}} | None | None | |
| Derived Summary Stage 2018 | 9 |
NAACCR #762
derivedSummaryStage2018 |
None | |
| Derived Summary Grade 2018 | <BLANK> |
NAACCR #1975
derivedSummaryGrade2018 |
None |